NasdaqGM - Delayed Quote • USD
Protagonist Therapeutics, Inc. (PTGX)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 5:19 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 5 |
| Avg. Estimate | 1.19 | 0.34 | 0.75 | -0.81 |
| Low Estimate | -0.62 | -0.66 | -2.71 | -3.27 |
| High Estimate | 3.95 | 4.19 | 2.49 | 2.14 |
| Year Ago EPS | -0.67 | -0.68 | -1.39 | 0.75 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 4 | 4 |
| Avg. Estimate | 120M | 60M | 152.5M | 137.5M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 300M | 300M | 300M | 330M |
| Year Ago Sales | -- | -- | 60M | 152.5M |
| Sales Growth (year/est) | -- | -- | 154.20% | -9.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.73 | -0.65 | -0.69 | -0.03 |
| EPS Actual | -0.67 | -0.68 | -0.58 | 0.44 |
| Difference | 0.06 | -0.03 | 0.11 | 0.47 |
| Surprise % | 8.20% | -4.60% | 15.90% | 1,566.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.19 | 0.34 | 0.75 | -0.81 |
| 7 Days Ago | 1.19 | 0.34 | 0.75 | -0.81 |
| 30 Days Ago | 2.22 | -0.61 | 0.82 | -0.81 |
| 60 Days Ago | 0.67 | -0.63 | -0.79 | -1.52 |
| 90 Days Ago | -0.64 | -0.65 | -2.6 | -1.78 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PTGX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 277.60% | -- | -- | 1.60% |
| Next Qtr. | 150.00% | -- | -- | 10.50% |
| Current Year | 154.00% | -- | -- | 5.20% |
| Next Year | -208.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/11/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/11/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 2/28/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 11/3/2023 |
| Initiated | Capital One: Overweight | 10/30/2023 |
Related Tickers
XNCR Xencor, Inc.
18.38
-3.01%
MLTX MoonLake Immunotherapeutics
42.19
-0.14%
IDYA IDEAYA Biosciences, Inc.
37.13
-1.30%
KRON Kronos Bio, Inc.
1.0100
-1.94%
PRAX Praxis Precision Medicines, Inc.
46.89
+0.64%
KURA Kura Oncology, Inc.
17.53
-0.85%
SWTX SpringWorks Therapeutics, Inc.
40.10
-5.58%
REPL Replimune Group, Inc.
6.45
-7.46%
PLRX Pliant Therapeutics, Inc.
12.52
+2.71%
MORF Morphic Holding, Inc.
27.99
+1.74%